CorriXR Therapeutics utilizes a CRISPR/Cas gene editing platform to disable drug resistance genes in tumor cells, specifically targeting squamous cell carcinoma of the head and neck. Their lipid nanoparticle delivery system minimizes off-target effects, enhancing the efficacy of cancer treatments.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers develop resistance to chemotherapy and targeted therapies, limiting treatment options and contributing to disease progression. Overcoming drug resistance requires innovative approaches that can selectively disable the genes responsible for resistance mechanisms within tumor cells.
Solution
CorriXR Therapeutics is developing a gene-editing platform that uses CRISPR/Cas technology to knock out drug resistance genes in cancer cells. The platform is initially focused on squamous cell carcinoma of the head and neck, with potential applications in other solid tumors. The company's approach involves a lipid nanoparticle delivery system designed to minimize off-target effects and enhance the precision of gene editing within the tumor microenvironment. By disabling resistance genes, CorriXR aims to resensitize tumors to existing therapies and improve patient outcomes.
Target Audience
The primary target audience includes oncology researchers and clinicians focused on developing new treatments for drug-resistant cancers, as well as patients with squamous cell carcinoma of the head and neck and other solid tumors.
Features
- CRISPR/Cas-based gene editing platform for disabling drug resistance genes
- Lipid nanoparticle delivery system for targeted intratumoral injection
- Focus on squamous cell carcinoma of the head and neck as initial target
- Potential applications in squamous cell carcinomas of the lung, esophagus, and pancreas, as well as melanoma, and glioblastoma
- Aims to resensitize tumors to existing therapies